ArticleMolecular cancer2021
Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma.
Open access · goldAbstract readLetter
In one paragraph
Article in Molecular cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 44 citations in OpenAlex.
- Proliferation Assessment by Trypan Blue Exclusion in Ewing Sarcoma.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Analysis of Colony Formation Capacity in Ewing Sarcoma.Methods in molecular biology (Clifton, N.J.) · 2027Article
- DNA replication stress and translational repression converge to drive CDK1- and caspase-dependent apoptosis in Ewing sarcoma.Oncogene · 2026Article
- Decreased expression of ribonucleotide reductase M2 accelerates ovarian aging by suppressing cell proliferation and inducing DNA damage in mouse theca-interstitial cells.Journal of ovarian research · 2026Article
- Combined Inhibition of ATR and Ribonucleotide Reductase Induces Synergistic Antineoplastic Activity in Osteosarcoma Cells.Cancer reports (Hoboken, N.J.) · 2026Article
- Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitors.Cell death & disease · 2026Article
- Integration of scRNA-seq and ST-seq identifies hyperproliferative RRM2+ cells features and therapeutic targets in gastric cancer.Journal of translational medicine · 2025Article
- Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells.Cancer research communications · 2025Article
- Ribonucleotide-diphosphate reductase subunit M2 (RRM2) expression and colorectal cancer invasiveness: a potential prognostic biomarker.Molecular biology reports · 2025Article
- Osalmid sensitizes clear cell renal cell carcinoma to navitoclax through a STAT3/BCL-XL pathway.Cancer letters · 2025Article
- Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing's sarcoma cells.BMC cancer · 2025Article
- Article
- Ribonucleotide reductase small subunit M2 promotes the proliferation of esophageal squamous cell carcinoma cellsActa pharmaceutica Sinica. B · 2024Article
- EWS-FLI1 and Activator Protein-1 (AP-1) Reciprocally Regulate Extracellular-Matrix Proteins in Ewing sarcoma Cells.International journal of molecular sciences · 2024Article
- Article
- A comprehensive analysis of ribonucleotide reductase subunit M2 for carcinogenesis in pan-cancer.PloS one · 2024Article
- Auranofin and reactive oxygen species inhibit protein synthesis and regulate the level of the PLK1 protein in Ewing sarcoma cells.Frontiers in oncology · 2024Article
- The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment.Cell & bioscience · 2023Article
- RRM2 as a novel prognostic and therapeutic target of NF1-associated MPNST.Cellular oncology (Dordrecht, Netherlands) · 2023Article
- Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cells.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 8 institutions in 1 country.
Shunya OhmuraHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Aruna MarchettoMax-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
Martin F OrthMax-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
Jing LiHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Susanne JabarPediatrics III, West German Cancer Centre, University Hospital Essen, Essen, Germany.
Andreas RanftPediatrics III, West German Cancer Centre, University Hospital Essen, Essen, Germany.
Endrit VincaHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Katharina CeranskiHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Martha J Carreño-GonzalezHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Laura Romero-PérezHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Fabienne S WehweckMax-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
Julian MusaHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Felix BestvaterLight Microscopy Facility, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
Maximilian M L KnottMax-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
Tilman L B HöltingMax-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
Wolfgang HartmannDivision of Translational Pathology, Gerhard-Domagk-Institute for Pathology, University Hospital Münster, Münster, Germany.
Uta DirksenPediatrics III, West German Cancer Centre, University Hospital Essen, Essen, Germany.
Thomas KirchnerInstitute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
Florencia Cidre-AranazHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Thomas G P GrünewaldHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. t.gruenewald@kitz-heidelberg.de.
Ludwig-Maximilians-Universität München · DEDeutschen Konsortium für Translationale Krebsforschung · DEHeidelberg University · DEGerman Cancer Research Center · DEHopp Children's Cancer Center Heidelberg · DEEssen University Hospital · DEUniversity Hospital Heidelberg · DEUniversity Hospital Münster · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Biomarkers, TumorAnimalsBone NeoplasmsDisease ManagementDisease Models, AnimalDisease SusceptibilityGene Expression Regulation, NeoplasticHumansMiceMolecular Targeted TherapyPrognosisPyridinesRibonucleoside Diphosphate ReductaseSarcoma, EwingThiosemicarbazonesXenograft Model Antitumor Assays3-aminopyridine-2-carboxaldehyde thiosemicarbazoneBiomarkers, TumorPyridinesRibonucleoside Diphosphate Reductaseribonucleotide reductase M2ThiosemicarbazonesChemoresistanceEwing sarcomaPaediatric oncologyPrognostic biomarkerRRM2Targeted therapyTriapine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.